GLP 3RT - R E T A
Stack Retatrutide & Get Tesamorelin 10% Discount
Retatrutide is an investigational triple-receptor agonist peptide (targets GLP-1, GIP, and glucagon receptors) under development for obesity and type 2 diabetes. Phase 2 trials demonstrated remarkable weight-loss efficacy, with patients losing up to 24% of body weight at 48 weeks on higher doses. This educational protocol presents a once-weekly subcutaneous approach with gradual titration to minimize gastrointestinal side effects.
Reconstitution Steps
Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Protocol Overview
Concise summary of the once-weekly regimen.
Goal: Support significant weight reduction and metabolic improvements through triple-receptor activation.
Schedule: Weekly subcutaneous injections for 12–48 weeks (clinical trials ranged 36–48 weeks).
Dose Range: 2–12 mg weekly with gradual 4-week titration steps.
Reconstitution: 3.0 mL per 30 mg vial (~10.0 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F) for up to 12 weeks.
Dosing Protocol
Suggested weekly titration approach from clinical trials.
Start: 2 mg weekly for 4 weeks to assess tolerance.
Escalate: Increase by 2–4 mg every 4 weeks as tolerated.
Target: 6–8 mg weekly (standard); 12 mg weekly (advanced/aggressive).
Frequency: Once per week (subcutaneous), same day each week.
Cycle Length: Minimum 24 weeks; trials extended to 48 weeks.
Timing: Any consistent day/time; rotate injection sites with each dose.
Storage Instructions
Proper storage preserves peptide quality and stability.
Lyophilized: Store at −20 °C (−4 °F) or colder in dry, dark conditions; stable for up to 24 months.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 12 weeks.
Allow vials to reach room temperature before opening to reduce condensation.
For extended storage, aliquot reconstituted solution and freeze at −20 °C (−4 °F); thaw only once before use.
Important Notes
Practical considerations for consistency and safety.
Use new sterile insulin syringes for each injection; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) systematically to reduce local irritation and lipohypertrophy.
For volumes >1.0 mL, split into 2 separate injections at different sites for better absorption.
Inject slowly; wait a few seconds before withdrawing the needle to ensure full dose delivery.
Document weekly dose, date, and injection sites to maintain consistency.
Gradual titration is essential to minimize gastrointestinal side effects; never skip escalation steps.
How This Works
Retatrutide’s unique mechanism of action stems from its triple-agonist design. By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies. Additionally, Retatrutide’s glucagon receptor agonism raises metabolic rate and promotes energy expenditure, further amplifying fat burning and weight loss beyond GLP-1/GIP effects alone. The peptide is engineered with a fatty-acid moiety to extend its circulation time (half-life ~6 days), allowing for once-weekly dosing. The combined hormonal activation leads to reduced calorie intake, increased satiety, and enhanced lipid oxidation, yielding potent weight loss and glycemic control. Preclinical studies confirmed that adding glucagon activity helps counteract the body’s adaptive slowing of metabolism during weight loss. In essence, Retatrutide tackles three metabolic pathways at once, resulting in greater efficacy in lowering blood glucose and body fat than single- or dual-agonist therapies.
Clinical Benefits & Side Effects
Observations from Phase 2 human clinical trials.
Benefits
Exceptional weight loss: Patients with obesity (without diabetes) lost an average of 22–24% of body weight at 48 weeks on 8–12 mg doses.
Glycemic control: In type 2 diabetes patients, HbA1c dropped by 1.3–2.0% (from ~8.0% to ~6.0%) with 4–12 mg doses; ~82% reached HbA1c ≤6.5%.
Cardiometabolic improvements: Reductions in blood pressure, LDL cholesterol, waist circumference, and liver fat content (>80% resolution of hepatic steatosis on high doses).
Universal response: 100% of participants on 8–12 mg achieved at least 5% weight reduction.
Side Effects
Gastrointestinal symptoms: Most common adverse effects were mild-to-moderate nausea, vomiting, and diarrhea, occurring primarily during dose escalation.
Side effects were dose-dependent and transient; gradual titration (4-week intervals) significantly reduced GI discomfort compared to rapid escalation.
No severe hypoglycemia or serious treatment-related adverse events reported in trials.
Safety profile comparable to GLP-1 agonists when properly titrated.
Injection Technique
Subcutaneous injection guidance from clinical best-practice resources.
Clean the vial stopper and injection site with alcohol; allow to dry completely.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
Do not aspirate for subcutaneous injections; inject slowly and steadily.
For volumes >1.0 mL, split into 2 injections at different sites (e.g., left and right abdomen).
Rotate sites systematically (abdomen preferred; also thighs, upper arms) to avoid lipohypertrophy.
Wait a few seconds after injecting before withdrawing needle to ensure full dose delivery.
Dispose of used syringes immediately in an FDA-approved sharps container.
